A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Vamorolone (Primary) ; Prednisone
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Acronyms VISION DMD
- Sponsors ReveraGen BioPharma
- 09 Apr 2018 Planned initiation date changed from 15 Mar 2018 to 30 Apr 2018.
- 19 Feb 2018 Status changed from planning to not yet recruiting.
- 17 Nov 2016 New trial record